[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. I Int J Cancer. 2015; 136(5): E359-86.
[2] Shen ZY, Xu LY, Li EM, et al. Immortal phenotype of the esophageal epithelial cells in the process of immortalization. Int J Mol Med. 2002; 10: 641-6.
[3] Jeong DY, Lee KS, Choi JY, et al. Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic Factors. Sci Rep. 2020; 10(1): 50774.
[4] Lu X, Zhou Y, Meng J, et al. Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoactivation, and favourable prognosis. Clin Epigenetics. 2020; 12(1): 23.
[5] Stankiewicz Karita HC, Magaret A, Huang ML, et al. Quantitative Oral HPV16 and HPV18 Detection in Persons Attending Dental Clinics. Sex Transm Dis. 2020; 47(2): 100-104.
[6] Peeters E, Wentzensen N, Bergeron C, Arbyn M. Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. Cancer Cytopathol. 2019; 127(3): 169-180.
[7] El-Zimaity H, Di Pilato V, Novella Ringressi M, et al. Risk factors for esophageal cancer: emphasis on infectious agents. Ann N Y Acad Sci. 2018; 1434(1): 319-332.
[8] Li S, Hong X, Wei Z, Xie M, et al. Ubiquitination of the HPV Oncoprotein E6 Is Critical for E6/E6AP-Mediated p53 Degradation. Front Microbiol.2019 10:2483.
[9] Sabu A, Mouli NVR, Tejaswini N, Rohit V, Nishitha G, Uppala D. Human Papillomavirus Detection in Oropharyngeal Squamous Cell Carcinoma Using p16 Immunohistochemistry. Int J Appl Basic Med Res. 2019; 9(4): 212-216.
[10] Gurín D, Slávik M, Shatokhina T, Kazda T, Šána J, Slabý O, Hermanová M. Current Perspective on HPV-Associated Oropharyngeal Carcinomas and the Role of p16 as a Surrogate Marker of High-Risk HPV. Klin Onkol.2019; 32(4):252-260.
[11] Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
[12] Ovestad IT, Dalen I, Hansen E, et al. Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program. Cancer Cytopathol. 2017; 125(4):283-291.
[13] Xi R, Pan S, Chen X, et al. HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo. Oncotarget. 2016; 7(35):57050-57065.
[14] Tasioudi KE, Sakellariou S, Levidou G, et al. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. APMIS. 2015; 123(8): 639-47.
[15] Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends Mol Med. 2018; 24(10): 856-870
[16] Zhang S, Cai J, Xie W, Luo H, Yang F. miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp Ther Med. 2018; 16(2): 1499-1504.
[17] Wu Shuhua, Wen Feifei, Li Yangyang, et al. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumour Biol. 2016, 37(7): 8799-809.
[18] Fatehi Hassanabad A, Chehade R, Breadner D, Raphael J. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr). 2019 Dec 17. [Epub ahead of print].
[19] Wang WL, Wang YC, Lee CT, et al. The impact of human papillomavirus infection on the survival and treatment response of patients with esophageal cancers. J Dig Dis. 2015; 16: 256–63.
[20] Bognár L, Hegedűs I, Bellyei S, et al. Prognostic role of HPV infection in esophageal squamous cell carcinoma. Infect Agent Cancer. 2018; 13:38.
[21] Kumar R, Ghosh SK, Verma AK, et al. p16 Expression as a Surrogate Marker for HPV Infection in Esophageal Squamous Cell Carcinoma Can Predict Response to Neo-Adjuvant Chemotherapy. Asian Pac J Cancer Prev. 2015; 16(16): 7161-5.
[22] Qian X, Nguyen DT, Dong Y, et al. Prognostic Score Predicts Survival in HPV-Negative Head and Neck Squamous Cell Cancer Patients. Int J Biol Sci. 2019; 15(7):1336-1344.
[23] Tang C, Lin L, Zhou W, et al. CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck. Chin J Cancer Res. 2019; 31(6):901-909.
[24] Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol. 2019; 39:33-40.
[25] Ludmir EB, Stephens SJ, Palta M, Willett CG, Czito BG. Human papillomavirus tumor infection in esophageal squamous cell carcinoma. J Gastrointest Oncol. 2015; 6(3):287-95
[26] Cao F, Zhang W, Zhang F, Han H, Xu J, Cheng Y. Prognostic significance of high-risk human papillomavirus and p16(INK4A) in patients with esophageal squamous cell carcinoma. Int J Clin Exp Med. 2014 7(10):3430-8
[27] Kahla S, Kochbati L, Maalej M, Oueslati R. Situation of HPV16 E2 gene status during radiotherapy treatment of cervical carcinoma. Asian Pac J Cancer Prev 2014; 15: 2869-2873.
[28] Wang P, Guan D, Zhang XP, Liu F, Wang W. Modeling the regulation of p53 activation by HIF-1 upon hypoxia. FEBS Lett. 2019; 593(18): 2596-2611.
[29] Zhang Y, Han CY, Duan FG, et al. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019; 19: 188.
[30] Zhu Q, Zhong AL, Hu H, et al. Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma. J Hematol Oncol. 2020; 13(1): 2.
[31] Wen C, Wang H, Wu X, et al. ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin. Cell Death Dis. 2019; 10(11): 809.
[32] Li D, Ji H, Niu X, et al. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2020; 111(1): 47-58.
[33] Perez-Juarez CE, Arechavaleta-Velasco F, Zeferino-Toquero M, Alvarez-Arellano L, Estrada-Moscoso I, Diaz-Cueto L. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors. Med Oncol. 2019; 37(1):4.
[34] Jung K, Kang H, Mehra R. Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). Cancers Head Neck. 2018; 3:3
[35] Xie J, Wang S, Li Z, et al. 5-aminolevulinic acid photodynamic therapy reduces HPV viral load via autophagy and apoptosis by modulating Ras/Raf/MEK/ERK and PI3K/AKT pathways in HeLa cells. J Photochem Photobiol B. 2019; 194: 46-55.
[36] Madera D, Vitale-Cross L, Martin D, et al. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Cancer Prev Res (Phila). 2015; 8(3): 197-207.